Controversies in the management of lentiginous melanoma in situ

Expert Review of Dermatology

Volumn 3, Issue 5, 2008, Pages 529-533

  Walling, Hobart W ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD; PARAFFIN;

CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; EDITORIAL; FROZEN SECTION; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LENTIGINOUS MELANOMA IN SITU; MALIGNANT LENTIGO; MELANOMA; PRIORITY JOURNAL; SURGICAL TECHNIQUE; TISSUE FIXATION; TOPICAL TREATMENT; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 55249112295     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.5.529     Document Type: Editorial

References (51)

1. Abdelmalek M, Abramova L, Hurt MA, Hruza G. The effectiveness of staged excisions for treating lentiginous melanoma in situ. Expert Rev. Dermatol. 3(5) 549-555, (2008).
2. Forman SB, Ferringer TC, Peckham SJ et al. Is superficial spreading melanoma still the most common form of malignant melanoma? J. Am. Acad. Dermatol. 58(6), 1013-1020 (2008).
3. Ferrara G, Zalaudek I, Argenziano G. Lentiginous melanoma: a distinctive clinicopathological entity. Histopathology 52(4), 523-525 (2008).
4. Charles CA, Yee VS, Dusza SW et al. Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists. Arch. Dermatol. 141(6), 723-729 (2005).
5. Davalbhakta A, Hamilton S, Grant JW, Lamberty BG. Spread of a recurrent lentigo maligna into a graft: a case for conservative treatment. Br. J. Plast. Surg. 54(3), 253-256 (2001).
6. Hill DC, Gramp AA. Surgical treatment of lentigo maligna and lentigo maligna melanoma. Australas. J. Dermatol. 40(1), 25-30 (1999).
7. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol. 33, 923-936 (1995).
8. Agarwal-Antal N, Bowen GM, Gerwels JW. Histologic evaluation of lentigo maligna with permanent sections: implications regarding current guidelines. J. Am. Acad. Dermatol. 47, 743-748 (2002).
9. Kelly JW. Following lentigo maligna may not prevent the development of life-threatening melanoma. Arch. Dermatol. 128(5), 657-660 (1992).
10. Michalik EE, Fitzpatrick TB, Sober AJ. Rapid progression of lentigo maligna to deeply invasive lentigo maligna melanoma. Report of two cases. Arch. Dermatol. 119(10), 831-835 (1983).
11. Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br. J. Dermatol. 116, 303-310 (1987).
12. Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft x-rays. Br. J. Dermatol. 146(6), 1042-1046 (2002).
13. de Moraes AM, Pavarin LB, Herreros F, de Aguiar Michelman F, Velho PE, de Souza EM. Cryosurgical treatment of lentigo maligna. J. Dtsch. Dermatol. Ges. 5(6), 477-480 (2006).
14. Schmid-Wendtner MH, Brunner B, Konz B et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J. Am. Acad. Dermatol. 43(3), 477-482 (2000).
15. Kuflik EG, Gage AA. Cryosurgery for lentigo maligna. J. Am. Acad. Dermatol. 31, 75-78 (1994).
16. Niiyama N, Niiyarna S, Takasu H, Katsuoka K. Progression of lentigo maligna into lentigo maligna melanoma following laser treatment. Eur. J. Dermatol. 17(3), 252-253 (2007).
17. Zalaudek I, Horn M, Richtig E. Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities. Br. J. Dermatol. 148, 703-708 (2003).
18. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch. Dermatol. 144(7), 943-945 (2008).
19. Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br. J. Dermatol. 155, 653-656 (2006).
20. Fisher GH, Lang PG. Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod crearn complicated by the development of invasive disease. Arch. Dermatol. 139(7), 945-947 (2003).
21. Naylor MF, Crowson N, Kuwahara R. Treatment of lentigo maligna melanoma with topical imiquimod. Br. J. Dermatol. 149(Suppl. 66), 66-70 (2003).
22. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol. Surg. 34(2), 147-151 (2008).
23. Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 55(6), 1398-1402 (1985).
24. Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br. J. Plast. Surg. 55, 611-615 (2002).
25. Pitman GH, Kopf AW, Bart RS, Casson PR. Treatment of lentigo maligna and lentigo maligna melanoma. J. Dermatol. Surg. Oncol. 5, 727-737 (1979).
26. Coleman WP 3rd, Davis RS, Reed RJ, Krementz ET. Treatment of lentigo maligna and lentigo maligna. melanoma. J. Dermatol. Surg. Oncol. 6, 476-479 (1980).
27. Huilgol SC, Selva D, Chen C et al. Surgical margins for lentigo maligna and lentigo maligna melanoma: the technique of mapped serial excision. Arch. Dermatol. 140, 1087-1092 (2004).
28. Robinson JK. Margin control for lentigo maligna. J. Am. Acad. Dermatol. 31, 79-85 (1994).
29. Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol. Surg. 26, 771-784 (2000).
30. Hazan C, Dusza SW, Delgado R, Busam KJ, Halpern AC, Nehal KS. Staged excision for lentigo maligna and lentigo maligna melanoma: a retrospective analysis of 117 cases. J. Am. Acad. Dermatol. 58(1), 142-148 (2008).
31. Bene NI, Healy C, Coldiron BM. Mobs micrographic surgery is accurate 95.1% of the time for melanoma in situ: a prospective study of 167 cases. Dermatol. Surg. 34(5), 660-664 (2008).
32. Bub JL, Berg D, Slee A, Odland PB. Management of lentigo maligna and lentigo Management melanoma with staged excision: a 5-year follow-up. Arch. Dermatol. 140(5), 552-558 (2004).
33. Kimyai-Asadi A, Katz T, Goldberg LH et al. Margin involvement after the excision of melanoma in situ: the need for complete en face examination of the surgical margins. Dermatol. Surg. 33(12), 1434-1439 (2007).
34. Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mobs micrographic surgery for lentigo maligna and lentigo maligna melanoma. J. Am. Acad. Dermatol. 57(4), 659-664 (2007).
35. Barlow RJ, White CR, Swanson NA. Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. Br. J. Dermatol. 146, 290-294 (2002).
36. Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J. Am. Acad. Dermatol. 37, 236-245 (1997).
37. Prieto VG, Argenyi ZB, Barnhill RL et al. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am. J. Clin. Pathol. 120(2), 203-208 (2003).
38. Weyers W, Bonczkowitz M, Weyers I, Bittinger A, Schill WB. Melanoma in situ versus melanocytic hyperplasia in sun-damaged skin. Assessment of the significance of histopathologic criteria for differential diagnosis. Am. J. Dermatopathol. 18(6), 560-566 (1996).
39. Hendi A, Brodland DG, Zitelli JA. Melanocytes in long-standing sun-exposed skin: quantitative analysis using the MART-1 immunostain. Arch. Dermatol. 142(7), 871-876 (2006).
40. Bhardwaj SS, Tope WD, Lee PK. Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma using Mel-5 immunostaining: University of Minnesota experience. Dermatol. Surg. 32(5), 690-696 (2006).
41. Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J. Am. Acad. Dermatol. 46(1), 78-84 (2002).
42. Dawn ME, Dawn AG, Miller SJ. Mohs surgery for the treatment of melanoma in situ: a review. Dermatol. Surg. 33(4), 395-402 (2007).
43. Bricca GM, Brodland DG, Zitelli JA. Immunostaining melanoma frozen sections: the 1-hour protocol. Dermatol. Surg. 30(3), 403-408 (2004).
44. Davis DA, Kurtz KA, Robinson RA. Ultrarapid staining for cutaneous melanoma: study and protocol. Dermatol. Surg. 31(7 Pt 1), 753-756 (2005).
45. Albertini JG, Elston DM, Libow LF, Smith SB, Farley MF. Mohs micrographic surgery for melanoma: a case series, a comparative study of immunostains, an informative case report, and a unique mapping technique. Dermatol. Surg. 28(8), 656-665 (2002).
46. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am. J. Dermatopathol. 26(5), 364-366 (2004).
47. Wiltz KL, Qureshi H, Patterson JW, Mayes DC, Wick MR. Immunostaining for MART-1 in the interpretation of problematic intra-epidermal pigmented lesions. J. Cutan. Pathol. 34(8), 601-605 (2007).
48. Helm K, Findeis-Hosey J. Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A. J. Cutan. Pathol. (2008) (Epub ahead of print).
49. McKenna JK, Florell SR, Goldman GD, Bowen GM. Lentigo maligna/lentigo maligna melanoma: current state of diagnosis and treatment. Dermatol. Surg. 32, 493-504 (2006).
50. Wildemore JK 4th, Schuchter L, Mick R et al. Locally recurrent malignant melanoma characteristics and outcomes: a single-institution study. Ann. Plast. Surg. 46(5), 488-494 (2001).
51. Bevona C, Fewkes J, Liu V, Sober AJ. Prolonged evolution of a lentigo maligna. J. Am. Acad. Dermatol. 51(5), 830-835 (2004).